Drug Profile
Research programme: antibacterials - Kosan/Johnson & Johnson
Alternative Names: JNJ 17156581; JNJ 17156815Latest Information Update: 25 Jun 2007
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development; Kosan Biosciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 26 Oct 2005 This programme is still in active development
- 30 Sep 2003 Data presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the Bacterial Infections antimicrobial activity and pharmacodynamics sections
- 14 Jan 2003 This collaboration between Kosan Biosciences, Johnson & Johnson Research & Development and Ortho-McNeil Pharmaceutical has been extended until 28 December 2003